V Portelli, S Cesare, B Galanti, G Genovese, M S Pappalardo, D Colimberti
{"title":"[Prospective study of HBV circulation and long-term evaluation of anti-hepatitis-B vaccination in patients undergoing hemodialysis].","authors":"V Portelli, S Cesare, B Galanti, G Genovese, M S Pappalardo, D Colimberti","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Hemodialysis patients were screened and monitored for HBV markers and at renal unit (identification EDTA 13ND) Palermo. Eighty-five patients received the hepatitis B vaccine (Haevac B Pasteur); fifty-three were followed up for more than three years; they received one of the three following schedules: 5 micrograms at 0, 1, 2 and 14 months; 5 micrograms at 0, 1, 2, 3, and 14 or 10 micrograms at 0, 1, 2, and 14 months. The best result was obtained by third schedule with a sero-conversion to anti-HBs of 83% at one month after the booster doses; and with the same percentage of anti-HBs positivity two years after the booster dose. During the study time (January 1984, March 1989) no new HBV events in patients and in the hemodialysis staff, who was also on monitoring, were observed.</p>","PeriodicalId":75613,"journal":{"name":"Bollettino dell'Istituto sieroterapico milanese","volume":"69 2","pages":"469-73"},"PeriodicalIF":0.0000,"publicationDate":"1990-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bollettino dell'Istituto sieroterapico milanese","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Hemodialysis patients were screened and monitored for HBV markers and at renal unit (identification EDTA 13ND) Palermo. Eighty-five patients received the hepatitis B vaccine (Haevac B Pasteur); fifty-three were followed up for more than three years; they received one of the three following schedules: 5 micrograms at 0, 1, 2 and 14 months; 5 micrograms at 0, 1, 2, 3, and 14 or 10 micrograms at 0, 1, 2, and 14 months. The best result was obtained by third schedule with a sero-conversion to anti-HBs of 83% at one month after the booster doses; and with the same percentage of anti-HBs positivity two years after the booster dose. During the study time (January 1984, March 1989) no new HBV events in patients and in the hemodialysis staff, who was also on monitoring, were observed.
对血液透析患者进行筛查和监测HBV标志物，并在巴勒莫肾科(鉴定EDTA 13ND)进行监测。85例患者接种了乙型肝炎疫苗(Haevac B Pasteur);其中53人随访超过3年;他们接受了以下三种方案中的一种:在0、1、2和14个月时摄入5微克;0、1、2、3、14个月时为5微克，0、1、2、14个月时为10微克。第三次方案效果最好，在加强剂量后1个月血清转化为抗- hbs的比例为83%;在注射加强剂两年后，抗乙肝病毒抗体呈阳性的比例也相同。在研究期间(1984年1月和1989年3月)，未观察到患者和接受监测的血液透析人员中出现新的HBV事件。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
